JP2012518029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518029A5 JP2012518029A5 JP2011550560A JP2011550560A JP2012518029A5 JP 2012518029 A5 JP2012518029 A5 JP 2012518029A5 JP 2011550560 A JP2011550560 A JP 2011550560A JP 2011550560 A JP2011550560 A JP 2011550560A JP 2012518029 A5 JP2012518029 A5 JP 2012518029A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- integer
- derivative
- moiety
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010054218 Factor VIII Proteins 0.000 claims 24
- 102000001690 Factor VIII Human genes 0.000 claims 24
- 229960000301 factor viii Drugs 0.000 claims 24
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000003601 transglutaminase Human genes 0.000 claims 2
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 claims 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims 1
- 241001495137 Streptomyces mobaraensis Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- ARMXDLIWGUZMEW-UHFFFAOYSA-N CC(NOBON)=O Chemical compound CC(NOBON)=O ARMXDLIWGUZMEW-UHFFFAOYSA-N 0.000 description 2
- VBCQTQTWKCGJMT-UHFFFAOYSA-N CC(NOBO/N=C/N)=O Chemical compound CC(NOBO/N=C/N)=O VBCQTQTWKCGJMT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153257.2 | 2009-02-19 | ||
| EP09153257 | 2009-02-19 | ||
| US16151009P | 2009-03-19 | 2009-03-19 | |
| US61/161,510 | 2009-03-19 | ||
| PCT/EP2010/052022 WO2010102886A1 (en) | 2009-02-19 | 2010-02-18 | Modification of factor viii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518029A JP2012518029A (ja) | 2012-08-09 |
| JP2012518029A5 true JP2012518029A5 (https=) | 2013-04-04 |
Family
ID=40935766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550560A Withdrawn JP2012518029A (ja) | 2009-02-19 | 2010-02-18 | 第ｖｉｉｉ因子の修飾 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110306551A1 (https=) |
| EP (1) | EP2398822B1 (https=) |
| JP (1) | JP2012518029A (https=) |
| CN (1) | CN102333788A (https=) |
| ES (1) | ES2401965T3 (https=) |
| WO (1) | WO2010102886A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
| CN106110311A (zh) | 2009-07-27 | 2016-11-16 | 百深公司 | 凝血蛋白缀合物 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN102497884A (zh) * | 2009-07-27 | 2012-06-13 | 巴克斯特国际公司 | 凝血蛋白缀合物 |
| JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| US20130040888A1 (en) * | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
| US20130345403A1 (en) * | 2010-12-16 | 2013-12-26 | Novo Nordisk A/S | Aqueous factor viii solution |
| HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| WO2013123409A1 (en) * | 2012-02-17 | 2013-08-22 | NVS Technologies, Inc. | Polymer scaffolds for assay applications |
| JP2015527350A (ja) * | 2012-08-13 | 2015-09-17 | ノヴォ ノルディスク アー／エス | 第ｖｉｉｉ因子の液体製剤 |
| EP2941423B1 (en) | 2013-01-07 | 2021-06-09 | University of Southern California | Deoxyuridine triphosphatase inhibitors |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
| SI2986313T1 (sl) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| WO2015000942A1 (en) | 2013-07-04 | 2015-01-08 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
| EP3019515B1 (en) * | 2013-07-11 | 2019-08-21 | Novartis AG | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| US9790214B2 (en) | 2014-01-03 | 2017-10-17 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
| WO2016011798A1 (zh) * | 2015-01-27 | 2016-01-28 | 深圳华大基因研究院 | 用于保存生物样品的稳定剂 |
| ES2772933T3 (es) | 2015-03-06 | 2020-07-08 | CSL Behring Lengnau AG | Factor de von Willebrand modificado que tiene una semivida mejorada |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| SI3319939T1 (sl) | 2015-07-08 | 2025-04-30 | Cv6 Therapeutics (Ni) Limited | Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017149070A1 (en) | 2016-03-03 | 2017-09-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| WO2019016300A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | EGF ANALOGUES (A), PREPARATION, FORMULATIONS AND USES THEREOF |
| EP3655427A1 (en) | 2017-07-19 | 2020-05-27 | Novo Nordisk A/S | Bifunctional compounds |
| WO2019229242A1 (en) | 2018-05-31 | 2019-12-05 | Novo Nordisk A/S | Derivatives comprising an apelin analogue and uses thereof |
| CN114072420B (zh) | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
| JP7680442B2 (ja) | 2019-11-11 | 2025-05-20 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
| MY206918A (en) | 2020-11-06 | 2025-01-17 | Novo Nordisk As | Glp-1 prodrugs and uses hereof |
| WO2023285334A1 (en) | 2021-07-12 | 2023-01-19 | Novo Nordisk A/S | Novel fatty acid modified urocortin 2 derivatives and the uses thereof |
| JP2025517672A (ja) | 2022-05-10 | 2025-06-10 | ノヴォ ノルディスク アー／エス | プロドラッグおよびその使用 |
| EP4612167A1 (en) | 2022-11-02 | 2025-09-10 | Novo Nordisk A/S | Cnp compounds |
| WO2024133739A1 (en) | 2022-12-22 | 2024-06-27 | Novo Nordisk A/S | Amylin receptor agonists |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| KR20240163292A (ko) * | 2023-05-10 | 2024-11-19 | 주식회사 아미노로직스 | 모노-터트-부틸 에스터화된 포화 탄화수소의 제조방법 및 이의 순환적 제조방법 |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| JP7826558B1 (ja) | 2024-10-11 | 2026-03-09 | ノヴォ ノルディスク アー／エス | ヒトｆｇｆ２３のアンタゴニスト |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| EP0555649B1 (en) | 1992-01-14 | 2004-12-08 | Ajinomoto Co., Inc. | Gene encoding transglutaminase derived from fish |
| DK128193D0 (da) | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
| JP3758187B2 (ja) | 1994-01-28 | 2006-03-22 | 味の素株式会社 | マガキ由来のトランスグルタミナーゼ |
| DE69535037T2 (de) | 1994-08-26 | 2006-12-07 | Novozymes A/S | Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung |
| WO1996022366A1 (en) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases from oomycetes |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| DE69840230D1 (de) * | 1997-05-16 | 2009-01-02 | Novozymes Inc | Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| WO2004075923A2 (en) * | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| EP2033662B1 (en) * | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| KR101468345B1 (ko) * | 2004-11-12 | 2014-12-03 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| CA2647314A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
-
2010
- 2010-02-18 EP EP10704152A patent/EP2398822B1/en not_active Not-in-force
- 2010-02-18 ES ES10704152T patent/ES2401965T3/es active Active
- 2010-02-18 JP JP2011550560A patent/JP2012518029A/ja not_active Withdrawn
- 2010-02-18 WO PCT/EP2010/052022 patent/WO2010102886A1/en not_active Ceased
- 2010-02-18 CN CN2010800074950A patent/CN102333788A/zh active Pending
- 2010-02-18 US US13/146,760 patent/US20110306551A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518029A5 (https=) | ||
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| JP2016153410A5 (https=) | ||
| JP2017536344A5 (https=) | ||
| JP2019512478A5 (https=) | ||
| JP2018504378A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2014516991A5 (https=) | ||
| JP2010521485A5 (https=) | ||
| JP2016534059A5 (https=) | ||
| JP2018521135A5 (https=) | ||
| JP2016536286A5 (https=) | ||
| JP2017515901A5 (https=) | ||
| JP2009536191A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| JP2018504379A5 (https=) | ||
| JP2021519076A5 (https=) | ||
| JP2012532136A5 (https=) | ||
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2017511321A5 (https=) | ||
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| JP2025081512A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| JP2012513416A5 (https=) | ||
| JP2014508804A5 (https=) |